SK5732002A3 - Imidazopyridine derivative as phosphodiesterase vii inhibitor, its use and pharmaceutical composition containing the same - Google Patents

Imidazopyridine derivative as phosphodiesterase vii inhibitor, its use and pharmaceutical composition containing the same Download PDF

Info

Publication number
SK5732002A3
SK5732002A3 SK573-2002A SK5732002A SK5732002A3 SK 5732002 A3 SK5732002 A3 SK 5732002A3 SK 5732002 A SK5732002 A SK 5732002A SK 5732002 A3 SK5732002 A3 SK 5732002A3
Authority
SK
Slovakia
Prior art keywords
formula
disorders
solvates
compounds
treatment
Prior art date
Application number
SK573-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Hans Michael Eggenweiler
Karl-August Ackermann
Rochus Jonas
Michael Wolf
Michael Gassen
Thomas Welge
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK5732002A3 publication Critical patent/SK5732002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
SK573-2002A 1999-11-06 2000-10-25 Imidazopyridine derivative as phosphodiesterase vii inhibitor, its use and pharmaceutical composition containing the same SK5732002A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953414A DE19953414A1 (de) 1999-11-06 1999-11-06 Imidazopyridinderivate als Phospodiesterase VII-Hemmer
PCT/EP2000/010525 WO2001034601A2 (de) 1999-11-06 2000-10-25 Imidazopyridinderivate als phosphodiesterase vii-hemmer

Publications (1)

Publication Number Publication Date
SK5732002A3 true SK5732002A3 (en) 2002-09-10

Family

ID=7928107

Family Applications (1)

Application Number Title Priority Date Filing Date
SK573-2002A SK5732002A3 (en) 1999-11-06 2000-10-25 Imidazopyridine derivative as phosphodiesterase vii inhibitor, its use and pharmaceutical composition containing the same

Country Status (22)

Country Link
US (1) US6613778B1 (da)
EP (1) EP1226143B1 (da)
JP (1) JP2003513973A (da)
KR (1) KR20020044591A (da)
CN (1) CN1387530A (da)
AR (1) AR026352A1 (da)
AT (1) ATE236157T1 (da)
AU (1) AU775993B2 (da)
BR (1) BR0015324A (da)
CA (1) CA2388729A1 (da)
CZ (1) CZ20021416A3 (da)
DE (2) DE19953414A1 (da)
DK (1) DK1226143T3 (da)
ES (1) ES2192183T3 (da)
HU (1) HUP0203245A3 (da)
MX (1) MXPA02004448A (da)
NO (1) NO20022124L (da)
PL (1) PL355022A1 (da)
PT (1) PT1226143E (da)
SK (1) SK5732002A3 (da)
WO (1) WO2001034601A2 (da)
ZA (1) ZA200204510B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0207215B8 (pt) 2001-12-13 2022-11-01 Daiichi Suntory Biomedical Res Limited Derivados de pirazolopirimidinona tendo ação de inibição de pde7
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
DK2433943T3 (da) 2004-07-01 2013-12-16 Daiichi Sankyo Co Ltd Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
BRPI0809244A2 (pt) * 2007-03-27 2014-09-23 Omeros Corp Métodos de tratamento de uma anormalidade de movimento, e para identificação de um agente que inibe a atividade pde7.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
AU2011326173B2 (en) 2010-11-08 2015-08-27 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3652180B1 (en) 2017-07-12 2023-11-29 Dart NeuroScience, LLC Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3150486A1 (de) * 1981-12-19 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US5120740A (en) * 1989-11-03 1992-06-09 Wisconsin Alumni Research Foundation Prodrugs of 6-mercaptopurine and 6-thioguanine

Also Published As

Publication number Publication date
DK1226143T3 (da) 2003-06-30
US6613778B1 (en) 2003-09-02
CA2388729A1 (en) 2001-05-17
HUP0203245A3 (en) 2003-12-29
DE19953414A1 (de) 2001-05-10
PL355022A1 (en) 2004-03-22
HUP0203245A2 (hu) 2003-01-28
JP2003513973A (ja) 2003-04-15
WO2001034601A2 (de) 2001-05-17
NO20022124D0 (no) 2002-05-03
DE50001663D1 (de) 2003-05-08
KR20020044591A (ko) 2002-06-15
WO2001034601A3 (de) 2001-11-15
NO20022124L (no) 2002-05-03
CZ20021416A3 (cs) 2002-08-14
ZA200204510B (en) 2003-11-26
ATE236157T1 (de) 2003-04-15
CN1387530A (zh) 2002-12-25
BR0015324A (pt) 2002-07-09
EP1226143A2 (de) 2002-07-31
EP1226143B1 (de) 2003-04-02
AU775993B2 (en) 2004-08-19
MXPA02004448A (es) 2004-09-10
ES2192183T3 (es) 2003-10-01
AR026352A1 (es) 2003-02-05
AU1387201A (en) 2001-06-06
PT1226143E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
SK5732002A3 (en) Imidazopyridine derivative as phosphodiesterase vii inhibitor, its use and pharmaceutical composition containing the same
SK5952002A3 (en) Pyrrole derivatives as phosphodiesterase vii inhibitor, the use thereof and pharmaceutical composition comprising the same
EP3080111A1 (en) Imidazopyridine derivatives as modulators of tnf activity
JP4819272B2 (ja) ホスホジエステラーゼｖｉｉ阻害剤として用いられるイミダゾール化合物
US7491742B2 (en) Imidazole derivatives as phosphodiesterase VII inhibitors
SK5942002A3 (en) Isoxazole derivatives to be used as phosphodiesterase vii inhibitors, use thereof and pharmaceutical composition comprising the same
JP4248245B2 (ja) ６−フェニルベンゾナフチリジン
SK4922002A3 (en) Imidazole derivative as phosphodiesterase vii inhibitor, use thereof and pharmaceutical composition containing the same
EP1675854B1 (en) Imidazopyridine-derivatives as inductible no-synthase inhibitors
DE10104802A1 (de) Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
EP0497609B1 (en) Pyrimido-benzothiazine derivatives for the treatment of inflammation, allergy and cardiovascular disease
JPH02264762A (ja) ５―トリフルオロメトキシ―２―ベンゾイミダゾールアミン、及びその製造及び使用方法
DE10104801A1 (de) Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (2)